Stoke Therapeutics Comes Out of Seed Mode With $40M and Ex-Sarepta CEO at Its Helm Post author:Sam Post published:January 3, 2018 Post category:BioPharma The Series A round was entirely funded by founding investor Apple Tree Partners. Source: BioSpace You Might Also Like Amgen's Repatha Reduces Cardiovascular Events in Patients with a History of Heart Attacks November 14, 2017 FDA Advisory Panel Spurns Pacira's Request for Expanded Use of Pain Drug Exparel February 15, 2018 Genentech Shows Off New Mid-Stage DME Data February 11, 2018
Amgen's Repatha Reduces Cardiovascular Events in Patients with a History of Heart Attacks November 14, 2017
